The Effect of Functional Dairy Products Enriched With Dietary Fibers on Human Health and Gut Microbiota
The purpose of this dietary intervention is to study the effects of dietary fibers on the gut microbiota and use yoghurt as the carrier.
Hypothesis 1: Intake of dietary fibers improves the blood lipid profile of the participants.
Hypothesis 2: Intake of dietary fibers stabilizes the gut microbiome (e.g., low diversity) of the participants, improves gut health and normalizes gastrointestinal function and bowel habits.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The study design is a parallel randomized, prospective, pre-post intervention trial. The main goal of this study is to investigate the effect of the dietary fibers in an unsweetened yoghurt. Fermented dairy products have naturally a very low dietary fiber content, but such products can be supplemented with variety of dietary fibers and promote the growth of beneficial gut bacteria. Also, as fermented milk products contain live bacteria, it is possible that prebiotic fibers could support the growth of the starter-culture based strains in the human gut.
PRE-STUDY EVALUATION AND TESTING
- Complete pre-study questionnaire
- Complete orientation to the study and provide voluntary consent to join the study
- Collection of coded intervention products, sampling supplies, and instructional materials 0-WEEK QUESTIONNAIRE AND LABORATORY VISIT
1. Record food intake and gastrointestinal function for 3 days 2. Collect health data and provide a 3-day food frequency questionnaire 3. Provide a stool and blood sample at the laboratory 2-WEEK QUESTIONNAIRE AND LABORATORY VISIT
- Record food intake and gastrointestinal symptoms for 3 days
- Collect health data and provide a 3-day food frequency questionnaire
- Provide a stool and blood sample at the laboratory BLOOD SAMPLE ANALYSES
1. Provide the blood sample at the laboratory in the morning in an overnight fasted state.
DIETARY INTERVENTION
1. Daily intake of a test or control product for two weeks.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Harjumaa
-
Tallinn, Harjumaa, Estonia, 12618
- Center of Food and Fermentation Technologies
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Age 25-55
- Normal bowel function
- Regular consumer of dairy products, willing to consume dairy products daily for 2 weeks
- Ability to provide a signed written informed consent
- Willing to provide stool and blood specimens 2 times over the 2-week study period
Exclusion Criteria:
- Diagnosed history of chronic diseases including coronary heart disease, stroke, cancer, type 1 or 2 diabetes mellitus, inflammatory bowel disease, gastritis, autoimmune disease, or rheumatoid arthritis
- Medication: statins, blood pressure medications, antidepressants, other prescription medications
- History of bariatric operation, removal of the gallbladder.
- Food allergies, lactose intolerance
- Recent (previous 3 months) use of antibiotics
- Intake of highly dosed pre- or probiotics 2 weeks prior and during the study
- Current pregnancy or breastfeeding
- Volunteers showing previously unrecognized illness will also be excluded
- Individual unable to give informed consent
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Scienza basilare
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Triplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Test group
Healthy adults consuming test product
|
200 g/day of unsweetened yogurt supplemented with a dietary fiber blend
|
|
Comparatore placebo: Control group
Healthy adults consuming control product
|
200 g/day of unsweetened yogurt
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Evaluation of the intestinal microbiota
Lasso di tempo: 14 days
|
Fecal microbiota analysis based on the 16S rRNA sequencing pre- and post-dietary intervention.
|
14 days
|
|
Evaluation of blood lipid profile
Lasso di tempo: 14 days
|
Triglycerides, total cholesterol, HDL-cholesterol, LDL-cholesterol pre- and post-dietary intervention in plasma (mmol/L).
|
14 days
|
|
Evaluation of blood glucose levels
Lasso di tempo: 14 days
|
Fasting glucose pre- and post-dietary intervention in plasma (mmol/L).
|
14 days
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Evaluation of the stool form
Lasso di tempo: 14 days
|
Stool form will be assessed using a validated 7-point scale called Bristol Stool Form Scale pre- and post-dietary intervention.
|
14 days
|
|
Evaluation of the defecation frequency
Lasso di tempo: 14 days
|
|
14 days
|
|
Evaluation of the defecation timing
Lasso di tempo: 14 days
|
Evacuation timing 3 days before sampling pre- and post-dietary intervention.
|
14 days
|
|
Evaluation of the gastrointestinal symptoms
Lasso di tempo: 14 days
|
Frequency and severity of the gastrointestinal symptoms (Constipation, Diarrhea, Bloating, Flatulence, Cramps, Stomach pain).
Scale of frequency: Never, Less than 10 times a year, Once a month, Once a week, Every day.
Scale of severity: I do not have any gastrointestinal symptoms, Mild (does not disturb), Moderate, Strong (disturbs considerably).
|
14 days
|
|
Evaluation of the blood vitamin D status
Lasso di tempo: 14 days
|
25-OH vitamin D pre- and post-dietary intervention in plasma.
|
14 days
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Madis Jaagura, MSc, TFTAK
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- 2014-2020.4.02.19-0198
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Anonymized participant data could be made available for subsequent analysis in the mentioned institution (TFTAK).
Data made public will include only aggregates or summaries of the collected data.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .